Full-Time

CADD / Application Scientist

Achira

Achira

11-50 employees

Atomistic drug-discovery simulation platform

Compensation Overview

$164.6k - $259k/yr

San Francisco, CA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid work is listed for the New York and San Francisco offices.

Category
Biology & Biotech (1)
Required Skills
Machine Learning
Medicinal Chemistry
Data Analysis

Get referred to Achira

See people who can refer or advise you

Requirements
  • Significant experience in computer-aided drug design, structure-based drug design, computational chemistry, medicinal chemistry collaboration, or related work in drug discovery.
  • Experience supporting or leading external collaborations with pharmaceutical, biotechnology, or discovery partners.
  • Strong intuition for protein-ligand binding, ligand poses, assay artifacts, protonation and tautomer states, waters, cofactors, ligand strain, and modeling workflow failures.
  • Ability to make expert judgments from imperfect data and identify benchmarks, application ideas, or partner case studies that matter to real discovery teams.
  • Ability and interest in working closely with machine learning researchers, simulation scientists, and platform teams.
Responsibilities
  • Shape training data strategy by identifying experimental, structural, partner-accessible, and synthetic data sources that could improve affinity prediction, selectivity, generalization, and downstream drug discovery utility.
  • Own end-to-end data and structure curation for high-value protein-ligand systems by connecting affinity measurements to assay context, preparing structures, assigning protein and ligand states, reviewing or generating poses, and labeling assumptions and uncertainty.
  • Work with model and training teams to interpret model successes and failures and distinguish data problems, setup problems, and model limitations.
  • Help decide which applications to pursue, including lead optimization, selectivity, pose assessment, scaffold transfer, affinity prediction, hit rescoring, and future extensions beyond potency.
  • Shape partner programs with business development and leadership by translating model capabilities into scientifically credible collaborations with pharmaceutical and biotechnology teams.
Desired Qualifications
  • Experience curating and running protein-ligand affinity or free energy perturbation benchmarks, including Open Free Energy or related evaluation efforts.
  • Experience across the full discovery arc from target identification through hit finding, hit-to-lead, and lead optimization.
  • Experience designing scientific case studies, technical reports, or partner-facing demonstrations for new computational methods.
  • Familiarity with machine learning-assisted drug discovery, active learning, synthetic data generation, or model evaluation for molecular systems.

Achira develops atomistic foundation simulation models for drug discovery, combining geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced potentials and generative models. These models produce large synthetic datasets free from experimental artifacts, enabling true inverse design where researchers optimize compounds from desired properties. Achira serves pharmaceutical and biotech clients through partnerships, licensing, and collaborations, differentiating itself by integrating physics-based simulations with data-driven learning to mitigate data scarcity and high costs. The company's goal is to accelerate and make drug discovery more reliable by enabling inverse design that reduces time and expenses in identifying promising compounds.

Company Size

11-50

Company Stage

Seed

Total Funding

$33M

Headquarters

New York City, New York

Founded

2024

Get referred to Achira

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Achira announced a $33M raise from Dimension, NVIDIA, Amplify, and Compound.
  • June 2026 BIO collaboration with NVIDIA expands distribution into life-sciences discovery workflows.
  • Hiring across ML, backend, and distributed systems shows active platform buildout in San Francisco and New York.

What critics are saying

  • Achira is still a 2024 company; product-market fit remains unproven by 2026.
  • Six open roles signal heavy burn before meaningful customer revenue arrives.
  • If NVIDIA or pharma partnerships stall, Achira becomes a research project, not a business.

What makes Achira unique

  • Achira pairs atomistic foundation models with physics, quantum chemistry, and geometric deep learning.
  • Its models generate synthetic molecular data, reducing dependence on scarce, artifact-prone experiments.
  • NVIDIA collaboration on molecular world models gives Achira compute and credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Flexible Work Hours

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

PTO/vacation

Paid Vacation

Paid Holidays

Unlimited Paid Time Off

401(k) Retirement Plan

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Confluence

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

28%
The National Herald
Apr 10th, 2025
Achira AI Secures $33M in Funding

Greek startup Achira AI has secured $33 million in funding from top investors, including Dimension, Nvidia, Amplify, and Compound. Achira aims to revolutionize AI-enabled drug development by integrating geometric deep learning, physics, quantum chemistry, and statistical mechanics to create advanced simulation models. This approach seeks to overcome limitations in current biomolecular simulations and machine learning models, accelerating the discovery of new molecules and treatments.

Endpoints News
Feb 21st, 2025
Nvidia-backed Achira debuts, blending AI and physics to model molecules

As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ultimately helped lead to his new job. The computational ...